Thermal Ablation for T1N0M0 Papillary Thyroid Carcinoma: A Long-term Multicenter Comparative Study with Subgroup Analysis
Academic Radiology · 2025-12 · 32 (12) · 7320-7330
DOI: 10.1016/j.acra.2025.09.019 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Academic Radiology, 2025-12. Verfasst von Han-Xiao Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Institute of Clinical Medical Sciences, Beijing, China (H.X.Z.); Department of Interventional Medicine, China-Japan Friendship…. Hauptthemen laut MEDLINE: Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the long-term efficacy of thermal ablation (TA) for T1N0M0 papillary thyroid carcinoma (PTC) and compare outcomes between unifocal T1a PTC and unifocal T1b PTC and between unifocal T1a PTC and multifocal (≤3 nodules) T1a PTC. MATERIALS AND METHODS: This multicenter retrospective study included 495 patients with T1N0M0 PTC from eight hospitals with a median follow-up of 79 months, including 397 unifocal T1a, 49 unifocal T1b, and 49 multifocal T1a patients. The primary outcomes were disease progression and disease-free survival. Secondary outcomes included the technical success rate, volume reduction rate (VRR), complete disappearance rate, and complications. Univariate and multivariate Cox regression analyses were performed to identify risk factors for disease progression. RESULTS: The disease progression rates were 4.3% (17/397) for unifocal T1a, 8.2% (4/49) for unifocal T1b, and 14.3% (7/49) for multifocal T1a PTC, with median follow-up durations of 81, 75, and 64 months, respectively. No significant differences were observed between the unifocal T1a and T1b groups (p=0.394), whereas progression was significantly higher for patients with multifocal T1a PTC than for patients with unifocal T1a PTC (p=0.010). New tumor development (4.4%) was more common than lymph node metastasis (LNMs) (1.8%) in the overall cohort. Among the 28 patients with disease progression, 25 underwent a second TA, with successful disease control in 96% (24/25) of the patients during a median follow-up of 40 months after retreatment. Multifocal tumors were the only independent risk factor for disease progression (HR: 5.601; p=0.001). Secondary outcomes included a 100% technical success rate, a 100% median VRR, and 99.0% complete tumor disappearance. The overall complication rate was 2.8%, with transient hoarseness being the most common major complication (2.2%). CONCLUSION: This long-term multicenter study demonstrated that TA is a safe and effective treatment for T1N0M0 PTC. Although multifocality was identified as an independent risk factor for disease progression, second ablation therapy can effectively control new tumors or LNM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- China-Japan Friendship Institute of Clinical Medical Sciences, Beijing, China (H.X.Z.); Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China (H.X.Z., Z.L.Z., L.L.P., Y.L., M.A.Y., Y.W.).
- Department of Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics and Traumatology, Yantai, China (S.R.W., J.K.L., L.Z.).
- Department of Medical Ultrasound, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China (L.H.L.).
- Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C.).
- Department of Ultrasonography, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China (S.S.W.).
- Department of Thyroid, Handan Hangang Hospital, Handan, China (S.N.H.).
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhao, H. X., Wang, S. R., Liu, L. H., Cong, Z. B., Wu, S. S., Li, J. K., Zhou, L., Huo, S. N., Shi, L. L., Wang, Z. H., Wei, Y., Zhao, Z. L., Peng, L. L., Li, Y., & Yu, M. A. (2025). Thermal Ablation for T1N0M0 Papillary Thyroid Carcinoma: A Long-term Multicenter Comparative Study with Subgroup Analysis. Academic Radiology, 32(12), 7320-7330. https://doi.org/10.1016/j.acra.2025.09.019
Vancouver
Zhao HX, Wang SR, Liu LH, Cong ZB, Wu SS, Li JK, et al. Thermal Ablation for T1N0M0 Papillary Thyroid Carcinoma: A Long-term Multicenter Comparative Study with Subgroup Analysis. Academic Radiology. 2025;32(12):7320-7330. doi:10.1016/j.acra.2025.09.019
BibTeX
@article{Zhao2025,
author = {Zhao, Han-Xiao and Wang, Shu-Rong and Liu, Li-Hong and Cong, Zhi-Bin and Wu, Song-Song and Li, Jin-Ke and Zhou, Lu and Huo, Sheng-Nan and Shi, Li-Li and Wang, Zhong-Hua and Wei, Ying and Zhao, Zhen-Long and Peng, Li-Li and Li, Yan and Yu, Ming-An},
title = {Thermal Ablation for T1N0M0 Papillary Thyroid Carcinoma: A Long-term Multicenter Comparative Study with Subgroup Analysis},
journal = {Academic Radiology},
year = {2025},
volume = {32},
number = {12},
pages = {7320--7330},
doi = {10.1016/j.acra.2025.09.019}
}
EUVIMED